PMCB · PharmaCyte Biotech, Inc. · Metrics
$0.36
+0.01 (+1.97%)
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— cleared Sep 14, 2026
The latest filing no longer states the doubt (first flagged Jul 29, 2026).
View the 10-Q filed Sep 14, 2026Market Cap
$3.76M
Shares
10.74M
Volume · Oct 27
47.71K
Avg daily vol (3M)
195.78K
PMCB metrics
61 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$0.35
Market cap
$3.76M
Price action
20 metricsPrice change (1W)
+2.4%
Price change (30D)
-16.6%
Price change (3M)
-40.2%
Price change (6M)
-54.1%
Price change (YTD)
-51.6%
Price change (1Y)
-64.2%
Trailing year
Price change (5Y)
-88.9%
52-week high
$1.22
52-week low
$0.34
Change from 52-week high
-71.3%
Change from 52-week low
+2.9%
Annualized volatility
99.1%
Annualized volatility (3M)
60.8%
Beta
1.8
RSI (14D)
35.9
Price vs SMA 50
-19.9%
Price vs SMA 200
-46.6%
Avg volume (3M)
195,779
Relative volume
0.1
Average dollar volume
$88,735
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
10.74M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.1
reciprocal yield 721.4%
FCF yield
—
TTM · current market cap
Buyback yield
10.5%
P / FCF
—
P / operating cash flow
—
Earnings yield
-423.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
10.5%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$0
Operating profit (TTM)
−$7.01M
Net income (TTM)
−$16.15M
Trailing 12 months
Diluted EPS (TTM)
$-2.08
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
-163.4%
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
-186.8%
Shares change YoY
+58.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-58.7%
Return on assets
-44.0%
Debt / equity
—
Current ratio
40.3
EBITDA (TTM)
−$1.92M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$17.74M
Total assets
$36.71M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$3.94M
Capital expenditures (TTM)
—
R&D (TTM)
$356,144
SG&A (TTM)
—
Stock compensation (TTM)
$892,500
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
32
13F filer change QoQ
-4
Institutional ownership
7.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
4.0%
Private-fund adviser ownership
3.2%
Active holders' share change QoQ
-20.5%
Holder tenure
8.3
Price vs estimated holder cost
-27.0%
Ownership (registered funds)
1 metricsIndex-fund ownership
2.0%
Short interest
3 metricsShort interest
0.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
19 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—